Close Menu

NEW YORK – Liquid biopsy firm Biocept said Monday that Blue Cross Blue Shield affiliate Highmark has made a positive coverage determination for Biocept’s Target Selector liquid biopsy test in the diagnosis and treatment of patients with non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.